GlassScriptPhysician profile
Muhammad I Ahmed
NPI 1588724561
$4,505.09
in general payments reported to CMS, 2019-2025
21 companies · $792 in 2025
The $792 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $140 · 2021: $201 · 2022: $535 · 2023: $1,200 · 2024: $908 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,891 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,891.39 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,251.94 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $503.88 | 2019-2025 | Ingrezza |
| Indivior INC. | $373.39 | 2022-2024 | Perseris, Sublocade |
| Otsuka America Pharmaceutical, INC. | $368.63 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $274.05 | 2019-2022 | |
| Abbvie INC. | $256.23 | 2021-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $244.41 | 2019-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $205.09 | 2022-2024 | Uzedy, Austedo Xr |
| Lundbeck LLC | $204.05 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $203.37 | 2021-2024 | Caplyta |
| Bioxcel Therapeutics, INC. | $127.10 | 2023-2024 | Igalmi |
| Allergan, INC. | $121.89 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $114.42 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $86.68 | 2019-2023 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $59.84 | 2023-2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $28.72 | 2023 | Epclusa |
| Astellas Pharma US INC | $19.62 | 2025 | Padcev |
| Alexion Pharmaceuticals, INC. | $17.60 | 2024 | Ultomiris |
| Braeburn INC. | $15.72 | 2024 | Brixadi |
| Tris Pharma INC | $14.77 | 2023 | Dyanavel Xr |
| Noven Therapeutics, LLC | $13.69 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.